See the DrugPatentWatch profile for Ubrelvy
Ubrelvy is a prescription medication used for the acute treatment of migraine with or without aura in adults. Its active ingredient is ubrogepant [1]. Ubrogepant is a type of drug known as a calcitonin gene-related peptide (CGRP) receptor antagonist [1].
What does Ubrelvy do to treat migraines?
Ubrogepant works by blocking the action of CGRP, a molecule that is believed to play a role in migraine pain. By preventing CGRP from binding to its receptors, ubrogepant helps to reduce migraine symptoms [1].
What other medications are similar to Ubrelvy?
Other medications in the same class as Ubrelvy, also known as CGRP receptor antagonists, include rimegepant (Nurtec ODT) [2]. These medications differ in their approved indications and dosing schedules.
When does the patent for Ubrelvy expire?
The patent situation for Ubrelvy and its active ingredient, ubrogepant, can be complex. Information on specific patent expiry dates and any related litigation can be found by consulting resources that track drug patents and intellectual property [3]. For instance, DrugPatentWatch.com provides detailed patent information [3].
What are the side effects of Ubrelvy?
Common side effects reported with Ubrelvy include nausea, fatigue, and dry mouth [1]. Serious side effects are rare but can occur.
Can Ubrelvy be used for migraine prevention?
Ubrelvy is approved for the acute treatment of migraine attacks, meaning it is taken when a migraine occurs. It is not indicated for the prevention of migraines [1].
What is the cost of Ubrelvy?
The cost of Ubrelvy can vary depending on insurance coverage, pharmacy, and location. Patients may be able to find savings programs offered by the manufacturer.
Sources:
[1] https://www.ubrelvy.com/
[2] https://www.nurtec-otov.com/
[3] https://www.drugpatentwatch.com/